Iodixanol
This non-ionic, iso-osmolar iodinated contrast agent is used for various diagnostic imaging procedures including cardiovascular angiography, CT scans, and myelography. Its iso-osmolar property minimizes the osmotic stress on blood vessels and kidneys during injection. It carries a lower risk of kidney injury compared to hyperosmolar agents, particularly in patients with pre-existing kidney disease.
Molecular Weight
1550.2000 g/mol
LogP
-3.40
TPSA
339.00 Ų
Lipinski RO5
Fail
Therapeutic Areas
Mechanism of Action
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChI
InChI=1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)
Molecular Formula
C35H44I6N6O15
HBD / HBA
13 / 15
Rotatable Bonds
22
Heavy Atoms
62
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This non-ionic, iso-osmolar iodinated contrast agent is used for various diagnostic imaging procedures including cardiovascular angiography, CT scans, and myelography. Its iso-osmolar property minimizes the osmotic stress on blood vessels and kidneys during injection. It carries a lower risk of kidney injury compared to hyperosmolar agents, particularly in patients with pre-existing kidney disease.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Iodixanol is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200507. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3724. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="iodixanol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/iodixanol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/iodixanol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/iodixanol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="iodixanol"></drugfyi-drug>